AMA Urges HHS to Withdraw Proposal Expanding Access to Certain Unapproved Peptides

November 19, 2026

The American Medical Association is urging the Department of Health and Human Services to withdraw a proposal that would expand access to certain unapproved peptides through compounding. The organization cited concerns about patient safety and the lack of FDA approval for the substances.

In a Nov. 11 letter to HHS, the AMA opposed what it described as a “rushed” decision to permit compounding of certain peptides that have not been approved by the FDA.

“We should not bypass the science and put patients at risk by making them guinea pigs for unapproved drugs,” said Willie Underwood III, president of the AMA, in the release. “If these substances are safe and effective, the evidence should demonstrate that through the FDA’s rigorous review process.”

According to the AMA, the proposal would allow compounding of peptides including BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. The organization noted that none of the substances have received FDA approval.

The AMA said allowing broader access to the peptides could expose patients to products with “unknown identity, purity, potency, dosing and safety.” The organization also said the FDA previously excluded the substances from the 503A Bulks List and that none are currently under review as part of an active Investigational New Drug application.

The letter urges HHS to require the peptides to undergo the FDA approval process, including clinical trials, before they are marketed or used clinically. “Just because a pharmacy can compound these peptides does not mean that consumers can or should trust the safety of such compounded substances,” the AMA wrote.

The statement follows adoption of new AMA policy calling on HHS and other entities to rescind policies that ease restrictions on compounding and distributing synthetic peptides that lack FDA approval.

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Health Canada Warns Against Unauthorized Peptides After Bacteria Found in Seized Products
    • FDA Authorizes Clinical Trials Evaluating Lynch Regenerative Medicine’s rhPDGF-BB for Facial Skin Quality and Infraorbital Hollows
    • Hims & Hers Launches Peptides+ for Men
    • Alpha Aesthetics Partners Launches Clinical Education for Platform Practices
    • Galderma’s Restylane Shaype Approved in Mexico for Chin and Jawline Enhancement